Savara Inc. (SVRA) - What Are Brokerages Saying About This Stock?

Savara logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Analysts’ consensus is “Moderate Buy”: Seven of eight analysts rate Savara a buy, while one recommends selling; the average 12-month price target is $10.25.
  • Recent calls are mixed: JPMorgan initiated coverage with an “overweight” rating and a $12 target, while Wall Street Zen downgraded the stock to “sell.”
  • Savara reported quarterly EPS of -$0.16, missing the -$0.14 consensus estimate. Shares opened at $4.83, compared with a 52-week range of $3.86 to $7.01.
  • MarketBeat previews the top five stocks to own by December 1st.

Shares of Savara Inc. (NASDAQ:SVRA - Get Free Report) have been assigned an average rating of "Moderate Buy" from the eight analysts that are presently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell rating and seven have assigned a buy rating to the company. The average 1 year price target among brokerages that have covered the stock in the last year is $10.25.

SVRA has been the topic of several recent analyst reports. Royal Bank Of Canada set a $10.00 price objective on shares of Savara in a research report on Wednesday, October 7th. Wall Street Zen downgraded Savara from a "hold" rating to a "sell" rating in a report on Sunday, October 4th. Weiss Ratings reissued a "sell (d-)" rating on shares of Savara in a research report on Thursday, October 15th. Citigroup reiterated a "market outperform" rating on shares of Savara in a research report on Wednesday, October 7th. Finally, JPMorgan Chase & Co. started coverage on shares of Savara in a research report on Wednesday, October 7th. They issued an "overweight" rating and a $12.00 target price for the company.

View Our Latest Report on Savara

Institutional Trading of Savara

Hedge funds have recently bought and sold shares of the company. Sterling Capital Management LLC boosted its holdings in shares of Savara by 842.8% in the third quarter. Sterling Capital Management LLC now owns 5,063 shares of the company's stock worth $26,000 after buying an additional 4,526 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. acquired a new stake in Savara in the third quarter valued at $54,000. Principal Financial Group Inc. acquired a new stake in shares of Savara in the 1st quarter valued at approximately $57,000. Sequoia Financial Advisors LLC purchased a new position in Savara during the second quarter worth about $69,000. Finally, E Fund Management Co. Ltd. bought a new position in Savara during the 2nd quarter valued at $77,000. Institutional investors own 87.93% of the company's stock.

Savara Price Performance

Shares of Savara stock opened at $4.83 on Friday. The company's 50-day moving average price is $4.98 and its two-hundred day moving average price is $5.37. Savara has a 52 week low of $3.86 and a 52 week high of $7.01. The stock has a market cap of $992.37 million, a PE ratio of -8.33 and a beta of 0.32. The company has a current ratio of 10.13, a quick ratio of 10.13 and a debt-to-equity ratio of 0.21.

Savara (NASDAQ:SVRA - Get Free Report) last posted its quarterly earnings data on Tuesday, August 11th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.14) by ($0.02). As a group, sell-side analysts anticipate that Savara will post -0.66 EPS for the current fiscal year.

Savara Company Profile

(Get Free Report)

Savara Inc is a clinical-stage biopharmaceutical company focused on developing therapies for rare respiratory diseases. The company's work is centered on conditions with significant unmet medical needs, particularly diseases involving impaired lung function and abnormal accumulation of material in the lungs.

Savara's lead product candidate is molgramostim, an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF). The therapy is being developed for autoimmune pulmonary alveolar proteinosis, a rare lung disorder in which surfactant accumulates in the airspaces and interferes with breathing.

Featured Stories

Analyst Recommendations for Savara (NASDAQ:SVRA)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Savara Right Now?

Before you consider Savara, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Savara wasn't on the list.

While Savara currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks That Could Lead the Next Market Boom Cover

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines